Progranulin induces adipose insulin resistance and autophagic imbalance via TNFR1 in mice

Bo Zhou*, Huixia Li*, Jiali Liu, Lin Xu, Qinyue Guo, Hongzhi Sun and Shufang Wu
The First Affiliated Hospital of Medical School of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi, China 710061
*(B Zhou and H Li contributed equally to this work)

Abstract

Progranulin (PGRN) has recently emerged as an important regulator for insulin resistance. However, the direct effect of PGRN in vivo and the underlying role of progranulin in adipose insulin resistance involving the autophagy mechanism is not fully understood. In this study, mice treated with PGRN for 21 days exhibited the impaired glucose tolerance and insulin sensitivity, remarkable adipose autophagy as well as attenuated insulin signaling via inhibition of mammalian target of rapamycin (mTOR) pathway. Furthermore, blockade of tumor necrosis factor receptor 1 (TNFR1) by TNFR1BP-Fc injection resulted in the restoration of impaired insulin sensitivity and insulin signaling induced by PGRN. Consistent with these findings in vivo, PGRN treatment induced defective insulin signaling, abnormal autophagic and mitochondrial activity in cultured adipocytes, while such effects were nullified by the blockade of TNFR1. In addition, PGRN-deficient adipocytes were more refractory to tunicamycin- or dexamethasone-induced insulin resistance, indicating the causative role of the TNFR1 pathway in the action of PGRN. Collectively, our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by inducing autophagy via the TNFR1-dependent mechanism.

Introduction

Progranulin (PGRN), also known as proepithelin, granulin/epithelin precursor or PC cell-derived growth factor, has recently emerged as an important regulator of glucose metabolism and insulin sensitivity. These studies showed that PGRN-deficient mice exhibited resistance to diet-induced obesity and insulin insensitivity through the modulation of inflammation, whereas adipocytes exposed to PGRN have increased susceptibility to be insulin-resistant and those effects can be normalized with treatment of pioglitazone, an insulin-sensitizing agent (Matsubara & Mita 2012). In particular, PGRN is more highly expressed in visceral adipose tissue of the insulin-resistant patients with morbid obesity than in their age-, sex- and BMI-matched insulin-sensitive counterparts (Youn et al. 2009), suggesting that progranulin can be a key adipokine to mediate insulin sensitivity and energy metabolism.

Although the role of progranulin in adipose tissue in obesity is not fully understood, its link with autophagy in other physiological and pathological processes in other cell types has now been identified. Recent studies revealed an abnormal accumulation of lipofuscin granules in mice...
brain regions with ablation of progranulin, accompanied by significantly increased p62 (Bjørkøy et al. 2005, Wils et al. 2012), suggesting impairment of the autophagy-lysosomal system in mice brains with ablation of progranulin. Furthermore, autophagy has been closely linked to inflammation in part by regulation of adipokine production. For example, mice with a conditional deletion of Atg7 in the intestinal epithelium showed an enhanced mRNA expression of IL1B (Crisan et al. 2011). Additional studies in vivo demonstrated that obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue, as evidenced by up-regulation of TNFA, IL1B and IL6 (Kawasaki et al. 2012). These observations raised the possibility that PGRN might be a promising new link among obesity, autophagy and insulin resistance.

Though the progranulin membrane receptor has not yet been identified, it is important to clearly define the early stages of progranulin-mediated signaling from the plasma membrane. Answers to these questions are of critical importance for two reasons. First, if progranulin has an effect in WT mice, it would firmly establish the critical role of progranulin in the pathogenesis of metabolic disorders; second, it would address the therapeutic potential of this new player in the regulation of energy metabolism. In this study, we therefore aimed to evaluate the potential role of progranulin and its predominant receptor in adipose tissue in vivo. We also provided the evidences that autophagic activity and intracellular events required for progranulin-mediated effects in adipocytes. Our results support the hypothesis that progranulin is a novel adipokine that aggravates insulin resistance via the activated autophagy and impaired insulin signaling in a TNFR1-dependent manner, indicating the importance of this novel player in the regulation of glucose metabolism and a promising therapeutic target in the treatment of metabolic diseases.

Material and methods

Preparation of recombinant mouse progranulin

The pFLAG-CMV1 vector was purchased from Addgene (Cambridge, MA, USA). pCAGIpuro was constructed by replacing the zeocin-resistant gene of pPCAGIZ with the puromycin-resistant gene. pCAGIpuro-FLAG was constructed by subcloning the insert encoding the prepro-trypsin signal peptide and FLAG epitope of pFLAG-CMV1 into pCAGIpuro. pCAGIpuro-FLAG was constructed by Sangon Biotech (Shanghai, China). pCAGIpuro-FLAGmPGRN was constructed by sub-cloning the insert encoding the mPGRN without signal peptide (amino acid 18–589) into pCAGIpuro-FLAG. Then we have transfected the pCAGIpuro-FLAG-mPGRN construct into CHO-K1 cells by electroporation (BTX, Holliston, MA, USA). The culture supernatants were collected and subjected to anti-FLAG M1 agarose affinity gel column (Sigma, A4596). Then the recombinant PGRN samples were analyzed by SDS–PAGE and coomassie blue staining. The protein bands were visualized at 88KD. Moreover, we used the mouse monoclonal anti-flag M1 antibody (Sigma, F3040) in immunoblot analyses, and the result showed that the full-length recombinant PGRN appeared as an 88 kDa FLAG-immunoreactive species. Finally, the purified PGRN were made endotoxin-free using the Detoxi-Gel endotoxin-removing column (Thermo Scientific, Rockford, IL, USA) as recommended by the manufacturer. As shown in Supplemental Fig. 1A, B and C, see section on supplementary data given at the end of this article, full-length progranulin can be found in 88 KD and adipocytes exposed to full-length progranulin showed considerable attenuation in insulin signaling and increase in autophagic activity, whereas elastase-digested PGRN had little effect on insulin signaling and autophagy in adipocytes.

Production of IgG1 Fc fused TNFR1 blocking peptide (TNFR1BP-Fc)

4 µg of plg/3C-TNFR1BP-Fc plasmid or plg/3C plasmid were co-transfected along with a pcDNA3.1 vector that contained a Neo gene into CHO-K1 cells using Lipofectamine 2000 as instructed (Invitrogen). After 24 h of transfection, the cells were selected with 800 µg/ml G418 (GIBCO, Grand Island, NY, USA) for 8 days. Single clones were obtained by limited dilution and maintained in the presence of G418.

TNFR1BP-Fc or IgG1Fc (as a control) was purified from the culture supernatants by chromatography using protein A-Sepharose CL-4B beads (Amersham Biosciences, Uppsala, Sweden). The unpurified and purified proteins were analyzed on 10% SDS–PAGE and stained with coomassie blue R250. The purified proteins were further passed through 0.45-µm filters (Millipore, Boston, MA, USA) for sterilization as described (Liang et al. 2008).

Animal care

The experimental procedures performed in this study were in accordance with the guidelines of the Institutional Animal Ethics Committee for the Care and Use of Laboratory Animals. For the in vivo study, C57BL/6j male...
mice (8 weeks old) were fed with a normal chow diet and housed under standard conditions with a 12 h light:12 h darkness cycle (darkness from 1930 to 0730 h). Mice were distributed in four groups (n = 10/group): i) vehicle (normal saline solution); ii) progranulin (i.p. 1 µg/g, once a day); iii) progranulin (i.p. 1 µg/g, once a day) + IgG1Fc (injection via tail vein, 1 µg/g, every three days); iv) progranulin (i.p. 1 µg/g, once a day) + TNFR1BP-Fc (injection via tail vein, 1 µg/g, every three days). The treatment lasted 21 days. At the end of the 21-day study period, half of the mice in each group were randomly selected and received an intraperitoneal injection of insulin at a dosage of 2 IU/kg; 15 min after the injection, the animals were euthanized, and their omental adipose tissues and blood samples were obtained and stored at −80 °C for subsequent analysis. To measure food intake, mice were individually housed in metabolic cages; they were given an unlimited supply of food and allowed to feed ad libitum. Food consumption was measured daily and mean daily consumption was calculated at the end of study.

Isolation and incubation of mouse adipocytes

Adipocytes were isolated from omental adipose tissue by collagenase (Type 1, Worthington Biochemical, Lakewood, NJ, USA) digestion. Cells were treated and incubated in supplemented Krebs-Ringer solution as described (Stralfors & Honnor 1989, Danielsson et al. 2005).

Cell culture

3T3-L1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM with 10% fetal bovine serum (FBS) (HyClone, Thermo Fisher Scientific, Inc. Logan, UT, USA). 3T3-L1 cells were induced to differentiate mature 3T3-L1 adipocytes with induction media by utilizing a standard protocol as described (Zhou et al. 2013a,b).

Measurement of blood parameters

Peripheral serum was subject to ELISA using standard kits (R&D Systems, Inc., Minneapolis, MN, USA) for progranulin. Morning blood glucose and insulin levels were measured and glucose tolerance testing (GTT) and insulin tolerance testing (ITT) were performed by utilizing a standard protocol as described (Zhou et al. 2013a,b). Glucose tolerance testing (GTT) was performed after the mice were fasted overnight. A total of 2 g/kg glucose was administrated through an i.p. injection, and blood glucose was measured at the indicated time points. Insulin tolerance testing (ITT) was performed after the animals had fasted for 4 h. Then, 0.75 U/kg insulin was administrated via i.p. injection, and blood glucose was measured at the indicated time points.

Electron microscopy analysis

Electron microscopy (EM) analysis was performed in omental adipose tissue samples by utilizing a standard protocol as described (Zhou et al. 2013a,b). Aorta samples were fixed in 4% paraformaldehyde/2% glutaraldehyde/0.1 M sodium cacodylate pH 7.3, post-fixed in 1% osmium tetroxide and embedded in epoxy resin (Epon). Ultrathin sections (80 nm) were stained with aqueous uranyl acetate and lead citrate and examined with a JEOL 2000FX transmission electron microscope (JEOL). For quantification of autophagolysosome-like vacuoles, the numbers of autophagolysosomal-like vacuoles were counted in each field and normalized by the surface area. Sixteen electron micrographs per mouse were digitized and the area and number of clearly distinguishable mitochondria were analyzed using OsteoMeasure software (OsteoMetrics, Decatur, GA, USA).

Glucose uptake

After transfer of 3T3L1 cells to medium without glucose, mouse adipocytes were incubated with 10 nmol/l insulin for 15 min, when glucose transport was determined as uptake of 50 µmol/l (10 µCi/ml) 2-deoxy-D-[1-3H] glucose, and then incubated 30 min. Uptake was linear for at least 30 min.

Gene silencing and gene expression analysis

Cells were transfected with a siRNA targeted for mouse PGRN (Santa Cruz, catalog number sc-39262), mouse TNFR1 (Santa Cruz, catalog number sc-36688) and mouse Atg7 (Santa Cruz, catalog number sc-41448 and Sigma, EMU094061) using Lipofectamine 2000 (Invitrogen). Gene silencing and real-time PCR was performed by utilizing a standard protocol as described (Zhou et al. 2013a,b). The real-time PCR primers included:

- **Atg7 For:** GGT CGC CCC CTT TAA TAG TGC, Rev: TGA ACT CCA ACG TCA AGCGG; p62 For: AGG ATG GGG ACT TGG TTGC, Rev: TCA CAG ATC ACA TTG GGG TGC; UCP1 For: AAG CGT ACC AAG CTG TGCGA, Rev: AGAAAA-GAAGC CAAAACCCCTT; Cebpa For: GAA TCT CCT AGT CTT GGTC, Rev: GAT GAGAACGCAACGAGTAC;
FABP4 For: ATG ATC AGC GGA AATGG, Rev: GCC TTT CAT AAC ACA TTCCA; Il6 For: ACA ACCACGGCCTTCCCTACTT, Rev: CAGATTTCCAGAAGACATGTG; Pgc1a For: AGC CAA ACC AAC TTT ATC TCTT, Rev: TTA AGG TTC GCT CAA TAG TCT TGTTCC.

**Western blot**

Tissues and cells under various treatments were lysed in lysis buffer containing 25 mM Tris–HCl (pH 6.8), 2% SDS, 6% glycerol, 1% 2-mercaptoethanol, 2 mM phenylmethylsulfonyl fluoride, 0.2% bromophenol blue and a protease inhibitor cocktail for 20 min. Western blotting was performed by utilizing a standard protocol as described (Wu et al. 2009).

**Antibodies**

The following antibodies were used: anti-Atg7, anti-p62, anti-LC3, anti-p-PERK, anti-PERK, anti-p-eIF2A and anti-eIF2A (Cell Signaling Technology Inc. Danvers, MA); anti-IRS-1, anti-pY20, anti-p-Akt, anti-Akt, anti-p-mTOR, anti-mTOR, anti-PGRN, anti-GAPDH (Santa Cruz Biotechnology, Inc.).

**Statistical analysis**

Statistical analyses were performed using SPSS 17.0 Software. Statistical analysis between the two groups was performed using unpaired, two-tailed Student t-test or ANOVA. Differences were considered significant when the P value was <0.05.

**Results**

**Effects of recombinant mouse progranulin on glucose metabolism, insulin sensitivity and mitochondrial activity via the TNFR1-dependent mechanism in vivo**

To evaluate the role of progranulin in insulin resistance, recombinant mouse progranulin was administrated intraperitoneally to mice under standard diet condition. We found that serum progranulin levels increased about twofold and the protein level of progranulin was also elevated in adipose tissue after treatment with progranulin for 21 days (Fig. 1A and Supplemental Fig. 1D, see section on supplementary data given at the end of this article). The alteration of Pgc1a expression was significantly reduced in adipose tissue of mice injected with progranulin compared to that of vehicle-injected mice (Fig. 1F and Supplemental Fig. 1H, see section on supplementary data given at the end of this article). The alteration of Pgc1a and Ucp1 expression indicated that progranulin treatment inhibited mitochondrial activity in the adipose tissue of mice. Consistent with these findings, morphology analysis of adipose tissue by EM showed decreased number and area of mitochondria in mice injected with progranulin compared with those of vehicle-injected mice (G and 1H). Meanwhile, the reduction in the expression level of Pgc1a and Ucp1 as well as the reduction in the number and area of mitochondria in adipose tissue of mice injected with progranulin was significantly neutralized by TNFR1BP-Fc. Moreover, we examined the expressions of adipogenic genes (Cebpa), adipose-specific genes (Fabp4), and inflammatory adipokines (Il6) in adipose tissue, which are involved in the development of insulin resistance. Progranulin injection increased Il6 expression, reduced Cebpa and Fabp4 expression, with these effects of progranulin being reversed by TNFR1BP-Fc (Supplemental Fig. 1I, J and K, see section on supplementary data given at the end of this article). These findings indicated that TNFR1BP-Fc partially blocks the effect of progranulin in vivo.

**Regulation of progranulin in autophagy and insulin signaling pathway via the TNFR1-dependent mechanism in adipose tissue of mice**

To understand the mechanisms for the effect of progranulin on insulin sensitivity and mitochondrial activity, we investigated whether progranulin could activate autophagy and impair insulin receptor signaling in mice. We first analyzed mRNA and protein expression of autophagy...
Progranulin induces autophagic imbalance via TNFR1

Figure 1
Effects of recombinant mouse progranulin (PGRN) on glucose metabolism, insulin sensitivity and mitochondrial activity via the TNFR1-dependent mechanism in vivo. All analyses compared age- and sex-matched mice fed a normal diet. Mice were divided into four groups: i) vehicle; ii) progranulin; iii) progranulin + IgG1Fc; iv) progranulin + TNFR1BP-Fc. (A) Serum progranulin. (B) Body weight. (C) Blood glucose. (D) Serum insulin. (E) Food intake. (F) Relative expression of Pgc1alpha in adipose tissue (real-time PCR). (G) Mitochondria number in adipose tissue. (H) Mitochondria area in adipose tissue. (I) Glucose tolerance testing (GTT). (J) Insulin tolerance testing (ITT). Data are expressed as means ± SD in each bar graph from ten mice per group. *P < 0.05 (vehicle vs PGRN). **P < 0.01. (PGRN + IgG1Fc vs PGRN + TNFR1BP-Fc).

Progranulin-induced autophagy in vivo: Autophagy is a physiological protective mechanism involved in the degradation of proteins and organelles. We found that progranulin injection led to increased expression of autophagy indicators in omental adipose tissue of mice, as evidenced by upregulation of Atg7 mRNA and protein level, and light chain 3 (LC3)-II protein levels. In contrast, mRNA and protein expression of p62 was reduced. Simultaneously, electron microscopic examination of adipose tissue showed a significant increase in autophagosome/autolysosome formation in mice treated with progranulin as compared with vehicle-injected mice and a reduction in mice injected with progranulin and TNFR1BP-Fc compared to the mice injected with progranulin and IgG1Fc. Considering the possibility that the increased levels of autophagy markers such as LC3-II seen in omental adipose tissue of mice injected with progranulin may reflect a lower turnover rather than increased autophagosome production, we treated omental adipose tissue explants with progranulin and TNFR1BP-Fc.
with chloroquine (a lysosomal protease inhibitor) or bafilomycin (an autophagy inhibitor), and monitored the formation of autophagosome. Remarkably, the expression of p62 and LC3-II was increased in omental adipose tissue explants of predisposed with PGRN and chloroquine/bafilomycin (A and B). In addition, to further confirm the association between autophagy and insulin resistance in omental adipose tissue explants, we predisposed omental adipose tissue explants with pioglitazone, a PPARgamma agonist that improves insulin sensitivity. As expected, we also observed that the increase of p62 and LC3-II was in adipose tissue (real-time PCR). (C) Protein expression of Atg7, p62 and LC3, and phosphorylation of mTOR in adipose tissue. (D) Quantification of autophagolysosome-like vacuoles per field in the EM images in adipose tissue. (E) Phosphorylation of IRS1 and Akt in adipose tissue. Data are expressed as means ± S.D. in each bar graph from ten mice per group and a representative blot is shown. *P<0.05 (vehicle vs PGRN). #P<0.05 (PGRN + IgG1Fc vs PGRN + TNFR1BP-Fc).

**Effects of progranulin on autophagy and insulin sensitivity in 3T3-L1 adipocytes**

To identify the role of progranulin in insulin resistance in vitro, we first elucidated the effect of progranulin on autophagy in mature adipocytes. We treated mature 3T3-L1 adipocytes with 100 ng/ml progranulin for 20 h and measured the protein expression of indicators of autophagy and insulin receptor signaling by western blot.

Progranulin treatment, with or without insulin, not only significantly elevated protein expression of Atg7 and LC3-II, but also reduced mTOR phosphorylation and p62 expression (Fig. 4A), suggesting that protein levels of autophagy-related genes is mediated by progranulin in an insulin-independent manner. Since progranulin has been shown to be involved in the PI3K/Akt signaling pathway, we postulated that progranulin might indirectly affect insulin signaling via upregulation of autophagy indicators in mature adipocytes. As expected, insulin-stimulated phosphorylations of both IRS1 and Akt were decreased in mature adipocytes treated with progranulin (Fig. 4B). Furthermore, progranulin treatment significantly suppressed insulin-stimulated glucose uptake (Fig. 4C), and decreased the number and the area of mitochondria in 3T3-L1 adipocytes (Fig. 4D and E). Additionally, we also analyzed whether insulin resistance was due to increased autophagy directly. Atg7 siRNA was validated by measurement of reduced Atg7 protein expression by western blotting in Atg7 siRNA (Santa Cruz, catalog number sc-41448 and Sigma, EMU094061) transfected adipocytes (Fig. 4F and Supplemental Fig. 2B, C and D, see section on supplementary data given at the end of this article). As shown in Fig. 4G and H, and Supplemental Fig. 2C, D
and E, see section on supplementary data given at the end of this article, treatment of progranulin reduced phosphorylation level of Akt and glucose uptake in adipocytes, while phosphorylation level of Akt and glucose uptake had a significant increase in adipocytes co-treated with progranulin and Atg7 siRNA. Therefore, blockade of Atg7 partially reversed impaired insulin signaling and suppressed insulin-stimulated glucose uptake in adipocytes treated with progranulin.

Ablation of progranulin prevents tunicamycin- or dexamethasone-induced autophagy and impaired insulin signaling in 3T3-L1 adipocytes

To further confirm the action of progranulin on autophagy and insulin signaling, we first determined whether ablation of progranulin reverses tunicamycin-induced autophagy and impaired insulin signaling in mature 3T3-L1 adipocytes. Progranulin siRNA was validated by measurement of reduced progranulin protein expression by western blot in progranulin siRNA-transfected 3T3-L1 adipocytes (Fig. 5A, B, C and D). In the presence of tunicamycin, the expression of progranulin was elevated while effectively knocked down by concomitant transfection of progranulin siRNA in 3T3-L1 adipocytes (Fig. 5A). As expected, tunicamycin (an agent commonly used to induce endoplasmic reticulum stress, leading to insulin resistance) not only produced a significant increase in autophagy, as evidenced by up-regulation of Atg7 and LC3-II protein expression and downregulation of p62 expression (Fig. 5A), but also decreased insulin-stimulated tyrosine phosphorylation of IRS1 and Akt Ser-473 (Fig. 5B). However, blockade of progranulin by transfection with progranulin siRNA in adipocytes reversed the effect of tunicamycin (Fig. 5A and B). In addition, we found that ablation of progranulin also prevented dexamethasone-induced autophagy and impaired insulin signaling in 3T3-L1 adipocytes (Fig. 5C and D). These observations further identified the effect of progranulin on insulin sensitivity in 3T3-L1 adipocytes.

TNFR1BP-Fc or TNFR1 siRNA blocks the effect of TNFR1-mediated progranulin in 3T3-L1 adipocytes

Based on our findings that TNFR1 is involved in the regulation of progranulin function in vivo, we postulated that TNFR1 could be a specific receptor for progranulin.
Progranulin induces autophagic imbalance via TNFR1

To confirm the hypothesis, we suppressed TNFR1 expression via TNFR1BP-Fc and TNFR1 siRNA in mature 3T3-L1 adipocytes in the presence of progranulin. TNFR1 siRNA-transfected 3T3-L1 adipocytes exhibited reduced TNFR1 protein expression compared with control siRNA-transfected 3T3-L1 adipocytes (Fig. 7A). Progranulin treatment reduced mTOR phosphorylation and insulin-stimulated glucose uptake, increased protein expression of autophagy indicators and autophagysmos number, impaired insulin signaling and induced insulin resistance, but blockade of TNFR1 by the addition of TNFR1BP-Fc in the culture medium or transfection with TNFR1 siRNA nullified the effect of progranulin in 3T3-L1 adipocytes (Fig. 6A, B, C, D, E and F, Fig. 7A, B, C, D, E and F; Supplemental Fig. 2F and G, see section on supplementary data given at the end of this article). Furthermore, we also

Figure 4
Effects of progranulin on autophagy and insulin sensitivity in 3T3-L1 adipocytes. 3T3-L1 adipocytes were cultured in the presence or absence of 100 nM progranulin (PGRN) 100 ng/ml for 20 h with or without Atg7 siRNA (Santa Cruz, catalog number sc-41448). (A) Protein expression of Atg7, p62 and LC3, and phosphorylation of mTOR. (B) Phosphorylation of IRS1 and Akt. (C) Effects of progranulin on glucose uptake. (D) Mitochondria number. (E) Mitochondria area. (F) Protein expression of Akt and LC3, and phosphorylation of mTOR. (B) Phosphorylation of IRS1 and p62, and LC3 in adipocytes treated with tunicamycin. (PGRN) siRNA. (A) Protein expression of progranulin, atg7, p62 and LC3 in adipocytes treated with tunicamycin. (C) Protein expression of progranulin, Atg7, p62 and LC3 in adipocytes treated with dexamethasone. (D) Protein expression of progranulin and phosphorylation of IRS1 and Akt in adipocytes treated with dexamethasone. A representative blot from three independent experiments is shown.

Figure 5
Ablation of progranulin prevents tunicamycin- or dexamethasone-induced autophagy and impaired insulin signaling in 3T3-L1 adipocytes. 3T3-L1 adipocytes were cultured in the presence or absence of 100 nM progranulin (PGRN) siRNA. (A) Protein expression of progranulin, Atg7, p62 and LC3 in adipocytes treated with tunicamycin. (B) Protein expression of progranulin and phosphorylation of IRS1 and Akt in adipocytes treated with tunicamycin. (C) Protein expression of progranulin, Atg7, p62 and LC3 in adipocytes treated with dexamethasone. (D) Protein expression of progranulin and phosphorylation of IRS1 and Akt in adipocytes treated with dexamethasone. A representative blot from three independent experiments is shown.
Recent evidence indicated that progranulin mediates high-fat-diet-induced insulin resistance and obesity through inducing the expression of IL6, and ablation of progranulin protected against high-fat-diet-induced obesity and insulin resistance. Of note, the respiratory quotient in mice with ablation of progranulin fed a high-fat diet was significantly lower at dark phase (Matsubara & Mita 2012), suggesting that ablation of progranulin suppressed high-fat-diet-induced obesity by consuming lipids more preferentially than carbohydrate. In line with these results in vivo, we also found that ablation of progranulin reverses tunicamycin-induced autophagy and impaired insulin signaling in mature adipocytes. Accordingly, progranulin may partly participate in chronic inflammation associated with insulin resistance and obesity, but the definite effect of progranulin in humans remains to be determined.

A recent study implicates the causative role of progranulin in the pathogenesis of the adipose insulin resistance of obese mice (He et al. 2002). However, the mechanisms of this defect could be diverse. Since obesity is characterized with enhanced intracellular lipid accumulation (Ost et al. 2010), the role of progranulin with sustained lipogenesis might be much more complicated than expected. It is plausible that chronic lipid overloading, which might impair insulin signaling and insulin-stimulated glucose uptake, might be one of the triggers in metabolic disturbance. Thus, systematic investigation of the metabolic consequences of progranulin administration is warranted in animals with the absence of other chronic changes that accompany the obese state. Our study demonstrated that mice treated with progranulin under standard diet conditions exhibited abnormal ITT and impaired insulin signaling with autophagy

Discussion

Recent evidence indicated that progranulin mediates high-fat-diet-induced insulin resistance and obesity through inducing the expression of IL6, and ablation of progranulin protected against high-fat-diet-induced obesity and insulin resistance in vivo (Matsubara & Mita 2012). Consistent with these findings, we also found that mice injected with progranulin developed glucose intolerance and insulin insensitivity. Of note, the respiratory quotient in mice with ablation of progranulin fed a high-fat diet
Recently, it has been shown that PGRN binds to TNFR, interfering with the interaction between TNFA and TNFR (Tang et al. 2011), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Recently, it has been shown that PGRN binds to TNFR, interfering with the interaction between TNFA and TNFR (Tang et al. 2011). When compared with TNFA?PGRN exhibited a higher affinity to both TNFR1 and TNFR2, and PGRN has approximately 600-fold higher binding affinity than TNFA (Bluml et al. 2010, Faustman & Davis 2010). Similar to PGRN, Atsttrrin, an engineered protein made of three PGRN fragments, inhibited the interaction between TNF and TNFR and, in turn, the downstream events of TNF/TNFR signaling. In contrast to TNFA, Atsttrrin exhibited a higher binding affinity for TNFR2, but a lower affinity for TNFR1 (Kessenbrock et al. 2008). Consistent with these findings, we also showed that blockade of TNFR1 partially reversed progranulin-induced insulin resistance. It has been well demonstrated that blockade of TNF signaling protected Wistar rats from high-fat-diet-induced obesity and adiposity, and TNFA neutralizing antibodies have been used to block TNFA bioactivity clinically as a therapeutic approach for obesity and insulin resistance (Liang et al. 2008). As indicated earlier, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.

It has been reported that mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes and insulin resistance. Increased intracellular fat disturbances, indicating that progranulin has a direct and causative role in insulin resistance in vivo.

Although PGRN plays crucial roles in multiple physiological and pathological conditions, efforts to exploit the actions of PGRN and understand the mechanisms involved have been hampered by the inability to identify its binding receptor(s), and it is still hard to clearly define the early stages of PGRN-mediated signaling from the plasma membrane. Some report that PGRN action is not mediated through TNFR (Chen et al. 2013, Etemadi et al. 2013), while more studies suggest that PGRN is a TNFR antagonist or a co-factor for TNFA action (Liu & Bosch 2012). Currently, the expression of progranulin in blood and adipose tissues was markedly increased in obese mouse, and even ablation of progranulin prevented mice from high-fat-diet-induced obesity (Matsubara & Mita 2012). In our analysis, PGRN caused impaired insulin signaling mainly through TNFR1 rather than TNFR2 in vitro. Several other groups also independently reproduced the binding of PGRN to TNFR1 and TNFR2 and the inhibitory effect of this binding on TNFA-induced effects (Jian et al. 2013, Hu et al. 2014, Liu et al. 2014). Our findings support the notion that PGRN is a key regulator of insulin resistance and that PGRN may mediate its effects, at least in part, by binding to TNF receptors.
accumulation in the liver and skeletal muscle leads to impaired activity of mitochondrial oxidative phosphorylation and insulin resistance in high-fat-diet-induced obese mice (Petersen et al. 2003). Microarray analysis studies have recently shown that the expression of genes involved in mitochondrial oxidative metabolism is reduced in humans with insulin resistance and diabetes (Mootha et al. 2003, Patti et al. 2003). For example, Pyc1a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. In our study, expression of Pyc1a was significantly reduced in adipose tissue of mice receiving progranulin compared to that of vehicle-injected mice. Simultaneously, histomorphometric quantification also showed a decrease in the number and the area of mitochondria in the mice injected with progranulin. Based on these results, we postulated that mitochondrial dysfunction and insulin resistance are interrelated. Notably, it has been shown that mitochondrial flavoprotein apoptosis-inducing factor-knockout mice with impaired mitochondria activity are resistant to high-fat-diet-induced obesity and diabetes (Pospisilik et al. 2007), indicating that the relationship between mitochondrial function and insulin sensitivity is not straightforward.

TNFR1 and TNFR2 do not share homology in the cytoplasmic domains but exhibit a low degree of similarity in the ligand-binding region located in the extracellular domains, which suggests that they are capable of inducing distinct cellular responses (Liang et al. 2008). Some studies imply PGRN elicits its action more through TNFR2 than TNFR1, because disturbed the interaction of PGRN with TNFR2, and in turn abolished PGRN-mediated activation of Erk1/2 and Akt signaling and protection against apoptosis in response to ER-stress (Li et al. 2014). Autophagy induction is an indirect message that protein synthesis is in suspended state, and it is possible that it could benefit in restoration of activated ER stress due to unfolded protein response (Komatsu et al. 2005, Mortensen et al. 2010), thus we extrapolated enhanced autophagy may be a protective and de-compensatory response to increased ER stress or a process underlying increased cell death. In other physiological and pathological processes, it is clear that protein expression of autophagy genes is increased in adipose tissue of humans and mice in obesity (Zhou et al. 2009, Kovsan et al. 2011), but impaired autophagy with decreased expression of autophagy genes has been shown in liver of obese mice and tied to insulin resistance (Yang et al. 2010), suggesting that the expression of autophagy genes is different in adipose tissue and the liver of obese mice. Additionally, recent results showed that PGRN may induce cholangiocyte proliferation by inhibiting autophagy via the suppression of Sirt1 expression (DeMorrow & Francis 2015). It is possible that enhanced autophagy represents an integral part of the ER stress and contributes to be a protective response in adipose tissue of PGRN-injected mice. In parallel, our recent study indicated a complimentary effect of both TNFR1 and TNFR2 in mediating PGRN function in cultured adipocytes. These discrepancies might be possibly due the fact that there is a different distribution between TNFR1 and TNFR2 in different cell types, and the function of PGRN might be diverse in different tissues, which should warrant further investigations.

In conclusion, our present study revealed that administration of PGRN attenuated insulin signaling and triggered autophagy in vivo and in vitro studies, with such effects being drastically blocked by TNFR1BP-Fc, suggesting a causative role of TNFR1 in PGRN-induced impaired insulin sensitivity and implicating that decreasing PGRN levels by influencing its turnover or production is consequently a promising therapeutic approach applied to metabolic disorders.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-15-0075.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the programs from the National Natural Science Foundation of China (General Program no. 81370899, no. 81170741, no. 81472038 and no. 81500016), National Excellent Young Scientist Program (no. 81222026) and the New Century Excellent Talents in University from the Ministry of Education, China (NCET-08-0435).

Author contribution statement
B Z wrote the manuscript and researched data. H L, J L, L X and Q G researched data and contributed to the discussion. S W and H S contributed to the experimental designs and reviewed and edited the manuscript. H S is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements
We appreciate the technical support and materials from the electron microscope center of Xi’an Jiaotong University.
References


Wu S, Zhou B, Xu L & Sun H 2009 IRS-2, but not IRS-1, can sustain directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. PLoS ONE 9 e92743. (doi:10.1371/journal.pone.0092743)


Semiabor T, Mit M et al. 2010 PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metabolism 15 482–493. (doi:10.1016/j.cmet.201004005)


Received in final form 12 September 2015
Accepted 14 September 2015
Accepted Preprint published online 15 September 2015